Department of Thoracic Surgery, West China Hospital, Sichuan University/West China School of Nursing, Sichuan University, Chengdu, China.
Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China.
Nutr Cancer. 2024;76(8):707-716. doi: 10.1080/01635581.2024.2361508. Epub 2024 Jun 6.
To clarify the prognostic role of the Gustave Roussy immune (GRIm) score in lung cancer.
The PubMed, Embase, Web of Science, and China National Knowledge Infrastructure databases were searched up to March 30, 2024. The primary outcomes included overall survival (OS) and progression-free survival (PFS). Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to evaluate the associations between the GRIm score and survival, and subgroup analyses were performed based on pathological type (non-small cell lung cancer vs. small cell lung cancer), tumor stage (advanced vs. limited stage) and treatment approach (immune checkpoint inhibitor vs. surgery vs. chemotherapy).
Eight studies with 1,333 participants were included. The pooled results showed that a higher GRIm score predicted worse OS (HR = 1.96, 95% CI: 1.54-2.49, < 0.001) and PFS (HR = 1.64, 95% CI: 1.22-2.21, = 0.001). Subgroup analyses for OS and PFS showed similar results. However, subgroup analyses for PFS indicated that the association between the GRIm score and PFS was nonsignificant among patients with small cell lung cancer ( = 0.114) and among patients treated with chemotherapy ( = 0.276).
The GRIm score might serve as a novel prognostic factor for lung cancer. Additional studies are still needed to verify these findings.
阐明 Gustave Roussy 免疫（GRIm）评分在肺癌中的预后作用。
检索 PubMed、Embase、Web of Science 和中国知网数据库，截至 2024 年 3 月 30 日。主要结局包括总生存期（OS）和无进展生存期（PFS）。计算风险比（HR）和 95%置信区间（CI）来评估 GRIm 评分与生存之间的关联，并根据病理类型（非小细胞肺癌与小细胞肺癌）、肿瘤分期（晚期与局限期）和治疗方法（免疫检查点抑制剂与手术与化疗）进行亚组分析。
纳入 8 项研究，共 1333 名参与者。汇总结果表明，较高的 GRIm 评分预示着 OS 更差（HR = 1.96，95%CI：1.54-2.49， < 0.001）和 PFS 更差（HR = 1.64，95%CI：1.22-2.21， = 0.001）。OS 和 PFS 的亚组分析显示出相似的结果。然而，PFS 的亚组分析表明，GRIm 评分与 PFS 之间的关联在小细胞肺癌患者中无统计学意义（ = 0.114）和接受化疗的患者中无统计学意义（ = 0.276）。
GRIm 评分可能是肺癌的一种新的预后因素。仍需要进一步的研究来验证这些发现。
